Evidence map›Paper›PMID 40722938›Full record

ArticleAntioxidants (Basel, Switzerland)2025

Distinctive Effects of Fullerene C

Sholpan Askarova, Kseniia Sitdikova, Aliya Kassenova, Kirill Chaprov, Evgeniy Svirin, Andrey Tsoy, Johannes de Munter, Anna Gorlova, Aleksandr Litavrin, Aleksei Deikin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Effects of Water-Soluble CMolecules (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sholpan AskarovaCenter for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0001-6161-1671
Kseniia SitdikovaCenter for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
Aliya KassenovaCenter for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0002-3670-3600
Kirill ChaprovInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka 119071, Russia.ORCID 0000-0002-0258-1879
Evgeniy SvirinInstitute of General Pathology and Pathophysiology, Moscow 125315, Russia.ORCID 0000-0003-3501-574X
Andrey TsoyCenter for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0003-3818-3079
Johannes de MunterNeuroplast BV, 6222 NK Maastricht, The Netherlands.ORCID 0000-0001-7583-1464
Anna GorlovaInstitute of General Pathology and Pathophysiology, Moscow 125315, Russia.
Aleksandr LitavrinDepartment of Normal Physiology, Sechenov First Moscow State Medical University, Moscow 119991, Russia.ORCID 0009-0004-0460-4992
Aleksei DeikinLaboratory of Genetic Technology and Gene Editing for Biomedicine and Veterinary, National Research, Belgorod State University, Belgorod 308015, Russia.
Andrey NedorubovDepartment of Normal Physiology, Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Nurbol AppazovLaboratory of Engineering Profile Physical and Chemical Methods of Analysis, Korkyt Ata Kyzylorda University, Kyzylorda 120014, Kazakhstan.ORCID 0000-0001-8765-3386
Allan KalueffDepartment of Biosciences and Bioinformatics, Suzhou Municipal Key Laboratory of Neurobiology and Cell Signaling, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou 215123, China.
Anton ChernopiatkoInstitute of General Pathology and Pathophysiology, Moscow 125315, Russia.
Tatyana StrekalovaInstitute of General Pathology and Pathophysiology, Moscow 125315, Russia.

Funding

EU Marie-Curie Skłodowska" PhytoApp" 0101007642Ministry of Higher Education and Science of the Republic of Kazakhstan AP23485236Ministry of Higher Education and Science of the Republic of Kazakhstan BR24992841
6 · The paper itself

Abstract

Fullerenes and fullerenols exhibit antioxidant and anti-inflammatory properties, making them promising candidates for Alzheimer's disease (AD) therapy. Unlike conventional anti-inflammatory drugs, these compounds have multitargeted effects, including their ability to inhibit amyloid fibril formation. However, few studies have explored their efficacy in high-validity AD models. Female APPswe/PS1E9 (APP/PS1) mice and their wild-type (WT) littermates were orally administered with fullerene C

Indexed as

Alzheimer’s diseaseantioxidantsAPPswe/PS1E9 micefullerene C60fullerenol C60(OH)24

Identifiers

PMID40722938
PMCPMC12292005

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.